Evidence map›Paper›PMID 35513188›Full record

ArticleThe Journal of infection2022

Remdesivir use in COVID-19 patients might predispose bacteremia, matched case-control analysis.

Marko Lucijanic, Tomislav Cikara, Petra Bistrovic, Ivan Papic, Maja Ortner Hadziabdic, Nikolina Busic, Marina Lackovic, Natalia Cesar, Valentina Koscak, Josko Mitrovic and 2 more

Abstract readLetterComment
In one paragraph

Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Marko LucijanicHematology Department, University Hospital Dubrava, Zagreb, Croatia; University of Zagreb School of Medicine, Zagreb, Croatia. Electronic address: markolucijanic@yahoo.com.
Tomislav CikaraCardiology Department, University Hospital Dubrava, Zagreb, Croatia.
Petra BistrovicCardiology Department, University Hospital Dubrava, Zagreb, Croatia.
Ivan PapicPharmacy Deaprtment, University Hospital Dubrava, Zagreb, Croatia.
Maja Ortner HadziabdicCentre for Applied Pharmacy, Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
Nikolina BusicDepartment of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia.
Marina LackovicQuality Department, University Hospital Dubrava, Zagreb, Croatia.
Natalia CesarQuality Department, University Hospital Dubrava, Zagreb, Croatia.
Valentina KoscakQuality Department, University Hospital Dubrava, Zagreb, Croatia.
Josko MitrovicUniversity of Zagreb School of Medicine, Zagreb, Croatia; Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia; Clinical Immunology, Allergology and Rheumatology department, University hospital Dubrava, Zagreb, Croatia.
Bruno BarsicUniversity of Zagreb School of Medicine, Zagreb, Croatia; Department of Internal Medicine, University Hospital Dubrava, Zagreb, Croatia.
Tomo LucijanicEndocrinology Department, University Hospital Dubrava, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BacteremiaCOVID-19 Drug TreatmentAdenosine MonophosphateAlanineAntiviral AgentsHumansAdenosine MonophosphateAlanineAntiviral AgentsremdesivirBacteremiaBlood culturesImmunosuppressionSARS-CoV-2

Identifiers

PMID35513188
PMCPMC9060712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.